ExpiresNovember 21, 2022
Louisiana Medical Mutual Insurance Company (LAMMICO)
Clostridioides difficile is the top cause of healthcare acquired infections in the US. There are new developments in the fight against this epidemic: new practice guidelines, new antibiotics, and new tools. Regional multidisciplinary collaboratives and antibiotic stewardship strategies have had some successes in reducing the incidence of C. difficile. Clinicians can benefit from this overview of evidence-based guidelines, new tools, and prescribing alternatives for their patients.
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
Allergy and Immunology
Medical Genetics and Genomics
Physical Medicine and Rehabilitation
Psychiatry and Neurology
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
• Describe the relationship of C. difficile infection to antibiotic prescribing.
• Access and define the current recommendations of the CDC, the IDSA, or your professional society on preventing C. difficile.
• Participate in a multidisciplinary collaborative to reduce C. difficile in your institution or region, or bring the concept to your institution.
• Explain several promising strategies in the battle against C. difficile.
C. Diff, Difficile, infection, antibiotic stewardship
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement, Professionalism, Systems-based Practice
CME Credit Type
AMA PRA Category 1 Credit
Inpatient, Outpatient, Rural, Urban, VA/Military